Hepatitis B and hepatitis C are often mentioned in the same breath — both are bloodborne viral infections, both can quietly become chronic, and both are leading drivers of cirrhosis and liver cancer worldwide. But for a global-health desk tracking the World Health Organization’s 2030 elimination targets, the two diseases are not on the same trajectory at all. One difference explains most of the gap: hepatitis B has a highly effective vaccine; hepatitis C does not.
Two Bloodborne Viruses, Two Different Risk Profiles
Both viruses spread primarily through contact with infected blood or body fluids, but their dominant transmission routes diverge in ways that matter for prevention planning. Hepatitis B is most commonly transmitted from mother to child around birth, and can also spread through sexual contact, unsafe injections, or exposure to sharp instruments — the virus is present in blood, semen, and vaginal fluids. Hepatitis C, by contrast, spreads mainly through direct blood-to-blood contact, most often via shared needles for drug injection, unsafe medical procedures, or unscreened blood transfusions; mother-to-child and sexual transmission occur but are less common.
Once acquired, the two viruses behave differently too. A majority of adults who contract hepatitis C acutely — on the order of 55 to 85 percent — go on to develop chronic infection, and among those with chronic hepatitis C, the risk of cirrhosis within twenty years runs roughly 15 to 30 percent. Hepatitis B’s chronicity risk depends heavily on the age at infection, which is exactly why the mother-to-child transmission route is so consequential: infection acquired in infancy is far more likely to become lifelong than infection acquired as an adult.
The Scale of the Problem
Both infections sit among the world’s leading infectious-disease killers. An estimated 240 million people are living with chronic hepatitis B globally, alongside roughly 47 million people living with chronic hepatitis C. Each disease adds close to 0.9 million new infections a year. Combined, chronic viral hepatitis B and C killed an estimated 1.3 million people in the most recent WHO reporting year — a toll the WHO has described as equivalent to roughly 3,500 deaths every day, on par with several other major global infectious killers.
The trend lines, though, are moving in opposite directions. Hepatitis B deaths have been reported as rising over the past decade, while hepatitis C deaths have been reported as falling over the same period. That divergence is not a mystery to anyone tracking prevention tools — it maps almost exactly onto which disease has a vaccine.
Why One Has a Vaccine and the Other Doesn’t
A safe, highly effective hepatitis B vaccine has existed for decades, typically given as a birth dose followed by booster doses in infancy, and it offers close to complete protection against the virus. That single tool is the backbone of WHO’s hepatitis B control strategy: the global target is at least 90 percent coverage of both the birth-dose vaccine and the completed infant vaccine series, alongside universal screening of blood donations.
Hepatitis C has no equivalent. Decades of research have not produced a licensed vaccine, largely because the virus circulates in at least eight distinct genotypes with more than a hundred subtypes and mutates readily — a moving target that has defeated the single-antigen approach that worked so well for hepatitis B. In the absence of a vaccine, hepatitis C control leans entirely on a different lever: direct-acting antiviral medicines, which can cure more than 95 percent of people who complete treatment. The catch is access — treatment uptake has remained far below what elimination requires, with only a modest share of eligible patients reached since the antivirals became widely available.
What the 2030 Targets Actually Ask For
WHO’s viral hepatitis elimination strategy sets a common headline goal for both diseases — a 90 percent reduction in new chronic infections and a 65 percent reduction in deaths by 2030, measured against a 2015 baseline — but the underlying service targets diverge by disease, reflecting that vaccine-versus-no-vaccine gap:
- Universal precautions (both diseases): 100 percent of blood donations screened in a quality-assured way, and 100 percent safe injection practices in health facilities.
- Hepatitis B-specific: at least 90 percent coverage of the birth-dose vaccine and 90 percent coverage of the completed infant vaccine series.
- Hepatitis C-specific: harm-reduction targets such as roughly 300 sterile needles and syringes distributed per person who injects drugs annually, since there is no vaccine to fall back on.
- Shared diagnosis and treatment targets: at least 90 percent of chronic infections diagnosed and at least 80 percent of eligible people treated, for both diseases.
Progress against those targets has been uneven. Diagnosis rates for both diseases remain well below the 90 percent target — a substantial share of people living with chronic hepatitis B or C are reported as still unaware of their infection — and WHO has stated plainly that the world is not on track to meet the 2030 elimination goals as currently trending.
Why the Distinction Matters for Field Programs
For editors and program planners covering vaccine-preventable disease, the hepatitis B/C comparison is a useful case study in what a vaccine actually buys a health system. Hepatitis B’s trajectory is, in principle, a solved problem: coverage, cold chain, and birth-dose timing are logistics challenges layered on top of a tool that already works close to perfectly. Hepatitis C’s trajectory depends instead on case-finding and treatment-access infrastructure — testing capacity, supply of antivirals, and reaching populations, such as people who inject drugs, who are disproportionately affected but often least connected to routine health services. Two diseases, similar death tolls, and two structurally different paths to elimination — one waiting on coverage, the other waiting on a vaccine that does not yet exist.